Preclinical efficacy & intermediate endpoint biomarkers IDIQ contract in support of the prevent cancer preclinical drug development program
Active Awarded Last action
- Contract number
- 75N91024D00003
- Awardee
-
The Institute For Cancer Research UEI FF1XVJMDYVR1 Part of Temple University-Of The Commonwealth System Of Higher Education
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- Prevent IDIQ mato RFP Pre-Solicitation · 75N91023R00024 · Posted Dec 19, 2022
- Last date to order 55% complete
- IDV ceiling
- $149,995,000.00
- Maximum order
- $149,995,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 9 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Cancer Institute awarded a multiple-award indefinite-delivery contract to The Institute For Cancer Research on January 25, 2024, with a ceiling of $149,995,000 and an ultimate completion date of January 24, 2029. The contract supports the PREVENT Cancer Preclinical Drug Development Program, specifically focusing on preclinical efficacy and intermediate endpoint biomarkers in support of candidate chemopreventive and immunopreventive regimens.
Work is performed at The Institute For Cancer Research, a non-profit subsidiary of Temple University located in Cheltenham, Pennsylvania. The contract encompasses three technical pools: Preclinical Efficacy and Biomarkers, Preclinical Services for Product Development and Manufacturing, and Preclinical Toxicology and Pharmacology Testing. Task orders under this IDIQ focus on identifying pharmacodynamic and efficacy biomarkers, conducting preclinical product development with CGMP manufacturing support, and performing toxicology and pharmacology testing for cancer preventive agents under development.
The originating solicitation was posted December 19, 2022, with a due date of February 6, 2023, and the award followed on January 25, 2024. As a multiple-award vehicle, this contract is one of several awards under the same PREVENT program structure.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N91024D00003?
75N91024D00003 was awarded to The Institute For Cancer Research by National Cancer Institute (National Institutes of Health) on January 25, 2024.
How much is contract 75N91024D00003 worth?
75N91024D00003's own ceiling is $149,995,000. A single order can be worth up to $149,995,000.
Who can order from contract 75N91024D00003?
75N91024D00003 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N91024D00003 part of a contract vehicle?
Yes. 75N91024D00003 is part of PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ.
Was contract 75N91024D00003 competed?
The extent of competition for 75N91024D00003 was full and open competition. The government received 9 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV